Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial.

Atul Malhotra, Josef Bednarik, Sujatro Chakladar, Julia P Dunn, Terri Weaver, Ron Grunstein, Ingo Fietze, Susan Redline, Ali Azarbarzin, Scott A Sands, Richard J Schwab, Mathijs C Bunck

June 2024 Contemp Clin Trials

Synopsis of Social media discussions

The overall sentiment reflects mild interest and engagement, exemplified by comments like '@blueeyedboy88 Mam bezdech ale czytałam' which shows personal health relevance, and mentions of the publication's design and baseline characteristics, indicating a basic level of engagement. The tone is neutral and informational, with some users indicating a desire to learn more, but overall, the discussions suggest cautious recognition rather than strong enthusiasm or skepticism.

A
Agreement
 Neither agree nor disagree

Most discussions appear to acknowledge the study's importance or mention it factually, without strong disagreement or critique.

I
Interest
 Moderate level of interest

Participants show some curiosity about the subject, responding with brief mentions of their experiences or plans to read more.

E
Engagement
 Moderate level of engagement

Comments include references to personal health impacts and mentions of the study's design, indicating moderate active participation.

I
Impact
 Moderate level of impact

The discussions suggest an awareness of potential implications for treatment of sleep apnea, though few details indicate deep concern or widespread change.

Social Mentions

YouTube

2 Videos

Twitter

6 Posts

News

28 Articles

Metrics

Video Views

219

Total Likes

5

Extended Reach

33,272

Social Features

36

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Tirzepatide in Obesity and Sleep Apnea Treatment

Tirzepatide in Obesity and Sleep Apnea Treatment

This video discusses the potential of tirzepatide for treating obesity-related obstructive sleep apnea, based on the SURMOUNT-OSA phase 3 trial evaluating its safety and effectiveness over 52 weeks.

CONECTIMED

September 8, 2025

219 views

Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea in Obese Patients

Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea in Obese Patients

The clinical trial demonstrates that tirzepatide reduces the severity of obstructive sleep apnea and improves cardiometabolic parameters in obese patients after 52 weeks, offering a promising pharmacological option.

CONECTIMED

September 7, 2025

0 views

  • Ted Kyle
    @ConscienHealth (Twitter)

    RT @Obesidades_mx: @ConscienHealth -Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sam…
    view full post

    December 27, 2024

    1

  • Obesidades México
    @Obesidades_mx (Twitter)

    @ConscienHealth -Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial. Contemp Clin Trials. 2024.
    view full post

    December 27, 2024

    2

    1

  • William Lagakos
    @caloriesproper2 (Twitter)

    Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial https://t.co/Nchel08Az6
    view full post

    December 21, 2024


  • @ScienceGeekAI (Twitter)

    @blueeyedboy88 Mam bezdech ale … czytałem https://t.co/kYwao4mqMx
    view full post

    June 26, 2024


  • @ScienceGeekAI (Twitter)

    @bfialek Cierpię to czytałem https://t.co/kYwao4mqMx
    view full post

    June 24, 2024

    1

  • redGDPS Diabetes
    @redGDPS (Twitter)

    Bibliografía en @PubMedOnline Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Atul Malhotra et al. Contemp Clin Trials. 2024 Jun. https://t.co/Hm7RwgRgL7
    view full post

    June 23, 2024

Abstract Synopsis

  • The study examines the effectiveness and safety of tirzepatide in treating moderate to severe obstructive sleep apnea (OSA) in individuals with obesity, as traditional weight loss methods can be difficult.
  • The SURMOUNT-OSA trial is a randomized and placebo-controlled phase 3 study that includes 469 participants, with some receiving no current OSA treatment and others using positive airway pressure therapy, while all are also undergoing lifestyle interventions for weight reduction.
  • The primary outcome measures the difference in apnea hypopnea index after 52 weeks between the tirzepatide and placebo groups, alongside various secondary outcomes related to sleep quality, physical activity, and cardiometabolic health.